RICHMOND, Va. (WRIC) — The Federal Food and Drug Administration has issued an emergency use authorization for remdesivri, making it the first treatment authorized to fight COVID-19.
An announcement from the University of Virginia said the authorization clears the use of remdesivir for hospitalized adults and children with severe cases of COVID-19 — such as patients on ventilators.
The drug was originally developed by Gilead Sciences to fight ebola. Virginia Commonwealth University said the way remdesivir works is it slows the infection of healthy cells is by mimicking the appearance of part of the virus and infiltrating the enzyme viruses can use to replicate themselves.
UVA and VCU have both been conducting clinical trials of the drug.
Trial results from UVA show the drug helped patients with advanced cases of the novel coronavirus recover 31 percent faster than patients who did not receive it. In addition, the median recovery time for patients who received remdesivir was 11 days and 15 days for people who got a placebo.
Gilead Sciences said its goal is to have millions of doses available by the end of the year.
- Virginians are running out of time to mail in ballots; Here’s how to make sure your vote counts
- Police: Woman covered care-dependent husband with kitty litter after accident
- National poll: Joe Biden leads President Trump by 5 points one week from Election Day
- Elon Musk’s SpaceX to provide free Starlink internet for families in Texas school district
- Sen. Tim Kaine addresses racism allegations at VMI